Innate Pharma S.A. ADR (IPHA)

$IPHA The program will feature Pierluigi Porcu, M.D., Division Chief for Hematology and BMT at University of Kentucky, Lexington, a world expert in T-cell lymphomas, who will provide medical perspectives on results from the Phase 2 TELLOMAK trial, which evaluated lacutamab in patients with relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL). ZS Associates, leading experts in life sciences and healthcare markets, will describe the eligible U.S. cutaneous T-cell lymphoma patient population based on real-world claims data. Finally, Innate Pharma’s management will provide updates on the planned Phase 3 trial, regulatory pathway in CTCL, including path to potential accelerated approval in Sézary syndrome, and commercial opportunity for lacutamab. tomorrow update on phase 3 trial very important

$IPHA over 50 billion market worldwide

$IPHA it’s not limited to urothelial, breast, lung, and ovarian cancers

$IPHA https://chatgpt.com/share/68fd4ece-bcb0-8011-9140-f727f29f5eb7

$IPHA https://share.google/oNpFTYQ5Gipavh4RE

$IPHA got a "Buy" rating & $8.X target. Its cancer drug IPH4502 targets a huge $1.5 billion bladder cancer market. https://notreload.xyz/innate-pharma-receives-strong-buy-recommendation/

Make sure to have ticker GIPR on watch for tomorrow! That strong close is a signal—buyers aren’t done yet on GIPR. The setup is tight, momentum is building, and shorts look exposed. This could squeeze hard and take out $4.X+ quickly. Don't be late on GIPR bulls it's a beautiful setup. $NVX $IPHA $LITM $XPON ..9

$IPHA Really good write-up that perfectly summarizes IPHA's present situation. So if you want to bring your IPHA knowledge up to date or just discover IPHA, this is required reading. https://beyondspx.com/quote/IPHA/analysis/innate-pharma-s-strategic-refocus-unlocking-oncology-value-with-differentiated-assets-nasdaq-ipha

$IPHA: Innate Pharma downgraded to Market Perform from Outperform at Leerink Partners View More Stock Downgrades: https://www.briefing.com/calendars/updown?Filter=downgrades&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link

Leerink Partners updates rating for Innate Pharma ( $IPHA ) to Market Perform, target set at 10 → 2.

HC Wainwright & Co. has updated their rating for Innate Pharma ( $IPHA ) to Neutral.

$IPHA https://stocks.apple.com/AaJTU7c6gQYmyk2T87baPpA

#earnings after the close on Tuesday, September 16, 2025 and before the open on Wednesday, September 17, 2025 https://www.earningswhispers.com/calendar $EPM $GIS $FLUX $MANU $IPHA

$IPHA Source: GlobeNewswire News Room https://share.google/rk2c9evvmRbHMY72P

$IPHA $2.28. bid. DAC $1.94 (4.16.25). EXIT $7.50. BRIEF: Innate Pharma (IPHA) initiated with a Buy at BTIG, tgt $8.

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Innate Pharma. Is that bullish or bearish? $IPHA #Innate #RsiOversold #NASDAQ

$IPHA pt $3

$IPHA Dr. Sonia Quaratino, Innate’s CMO, highlighted the urgent need for new therapies in relapsed/refractory DLBCL and FL, highlighting the promising activity of IPH6501—including in rituximab-resistant scenarios—and its potential to improve outcomes when added to R-CHOP

$IPHA It’s currently being evaluated in a Phase 1/2 clinical trial (NCT06088654) for patients with relapsed/refractory CD20‑positive B‑cell non-Hodgkin lymphoma, with up to 184 patients expected to enroll

$IPHA IPH6501, Innate Pharma’s proprietary ANKET® (Antibody-based NK cell Engager Therapeutic) targeting CD20, demonstrated potent antitumor activity in preclinical settings, both in vitro and in vivo, against Diffuse Large B‑Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) patient-derived samples

$IPHA Innate Pharma presents preclinical data for IPH6501 at EHA Innate Pharma announced the presentation of preclinical data for IPH6501, its proprietary Anket targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory B-cell non-Hodgkin lymphoma, at the European Hematology Association Congress 2025, taking place June 12-15 in Milan, Italy. R-CHOP is an established standard of care for treatment-naive patients with diffuse large B cell lymphoma and follicular lymphoma, two subtypes of B-NHL. The treatment landscape continues to evolve with novel approaches including T cell engagers, antibody-drug conjugates, their combination with standard of care therapies, and CAR-T cells. Yet, there remains an unmet medical need for patients ineligible, refractory to, or relapsing from these therapies. In preclinical in vitro models, IPH6501 demonstrated potent NK cell proliferation and tumor cell killing activity in DLBCL and FL patient samples, supporting its therapeutic potential in these indications. In preclinical in vivo xenografted mouse tumor models, IPH6501 showed strong activity in a rituximab-resistant model - even in the presence of rituximab highlighting their combination potential. Additionally, when combined with R-CHOP, IPH6501 showed enhanced antitumor efficacy, leading to tumor eradication that was maintained after treatment discontinuation. These findings underscore the potential of IPH6501 in improving standard-of-care R-CHOP treatment in previously untreated DLBCL and FL patients and support further evaluation of additional combination strategies in B-NHL.

$IPHA Innate Pharma presents long-term follow-up data from TELLOMAK trial Innate Pharma announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sezary syndrome and mycosis fungoides, two rare and aggressive forms of cutaneous T-cell lymphoma. The results will be presented at the American Society of Clinical Oncology annual meeting, in Chicago, Illinois. As of October 17, 2024, data cut-off, lacutamab demonstrated compelling and sustained clinical activity in heavily pretreated patients, with a global ORR of 42.9% for SS and 19.6% for MF. With longer follow-up, we observed improved median duration of response of 25.6 months in SS and 13.8 months in MF, highlighting the durability of responses in these challenging indications. In addition, lacutamab was very well tolerated supporting the strong rationale for further investigations in combination beyond CTCL, especially in combination with other anti-lymphoma agents in peripheral T-cell lymphomas.